Persistent URL of this record https://hdl.handle.net/1887/4296167
Documents
-
- Download
- Full text
- Publisher's Version
-
open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
The vasopressin biomarker copeptin is linked to systemic inflammation and refines prognostication in decompensated cirrhosis
BACKGROUND & AIMS: Copeptin, an arginine-vasopressin biomarker, may confer prognostic information in patientswith advanced chronic liver disease (ACLD).
METHODS: Patients with ACLD included in the Vienna Cirrhosis Study (NCT03267615) between January 2017 and April 2023 and available copeptin levels were prospectively recruited and classified into 6 predefined clinical ACLD stages from S0 (subclinical portal hypertension) to S5 (further decompensation). A prognostic score (MELD-copeptin score) in patients with decompensated ACLD (dACLD) was developed in a derivation cohort (n = 150) and validated in an internal (n = 148) and an external validation cohort (n = 771).
RESULTS: Among 475 patients with ACLD, 177 were compensated, whereas 298 were decompensated. Median levels of copeptin increased with progressive ACLD severity (S0, 7.5 pmol/L vs S5, 14.3 pmol/L; P < .001). Copeptin (adjusted Beta, 0.10; P < .001) was independently associated with interleukin-6...
Show moreBACKGROUND & AIMS: Copeptin, an arginine-vasopressin biomarker, may confer prognostic information in patientswith advanced chronic liver disease (ACLD).
METHODS: Patients with ACLD included in the Vienna Cirrhosis Study (NCT03267615) between January 2017 and April 2023 and available copeptin levels were prospectively recruited and classified into 6 predefined clinical ACLD stages from S0 (subclinical portal hypertension) to S5 (further decompensation). A prognostic score (MELD-copeptin score) in patients with decompensated ACLD (dACLD) was developed in a derivation cohort (n = 150) and validated in an internal (n = 148) and an external validation cohort (n = 771).
RESULTS: Among 475 patients with ACLD, 177 were compensated, whereas 298 were decompensated. Median levels of copeptin increased with progressive ACLD severity (S0, 7.5 pmol/L vs S5, 14.3 pmol/L; P < .001). Copeptin (adjusted Beta, 0.10; P < .001) was independently associated with interleukin-6 levels in dACLD. In dACLD, copeptin was linked to higher risk of further decompensation (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P = .039), acute-on-chronic liver failure (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.01-1.02; P < .001), and liver-related death (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.01-1.02; P < .001) independently of relevant cofactors. The MELD-copeptin score yielded higher area under the receiver operating characteristics (AUROCs) for liver-related events than the MELD-Na score in the internal validation cohort, accurately predicting liver-related death at 6 months (AUROC, 0.777 vs MELD-Na, 0.673), 1 year (AUROC, 0.784 vs MELD-Na, 0.661), and 2 years of follow-up (AUROC, 0.741 vs MELD-Na, 0.636). Similarly, the MELD-copeptin score consistently yielded higher AUROCS for the development of liver-related death and acute-on-chronic liver failure at 3, 6, and 12 months of follow-up in the external validation cohort.
CONCLUSIONS: In patients with dACLD, copeptin is independently linked to systemic inflammation. The MELDcopeptin score identifies patients with dACLD at risk for impaired clinical outcomes.
Show less- All authors
- Hartl, L.; Hintersteininger, M.; Simbrunner, B.; Jachs, M.; Hofer, B.S.; Bauer, D.J.M.; Dominik, N.; Schwarz, M.; Balcar, L.; Kramer, G.; Kerbert, A.J.C.; Coenraad, M.J.; Thevenot, T.; Moreau, R.; Trebicka, J.; Clària, J.; Marculescu, R.; Trauner, M.; Mandorfer, M.; Reiberger, T.
- Date
- 2026-01-01
- Volume
- 24
- Issue
- 1
- Pages
- 131 - 140